Leadership
-
Stock via Getty Images
Milk-based therapies could be coming. This biotech CEO is aiming to lead the way.
Intrinsic Medicine is entering phase 2 trials in Parkinson’s disease and IBS for its human milk oligosaccharide drug candidates next year.
By Amy Baxter • Dec. 2, 2024 -
Kevin Dietsch / Staff via Getty Images
How the incoming administration could impact FTC’s approach to pharma M&A
Pharma companies looking to get a break from the FTC under a new administration may be out of luck.
By Kelly Bilodeau • Nov. 26, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
iStock via Getty Images
Q&A // Biotech SpotlightAn RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond
Stoke Therapeutics is entering phase 3 with its RNA medicine designed to treat a rare epileptic condition.
By Michael Gibney • Nov. 26, 2024 -
Noam Galai via Getty Images
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA
A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the pandemic, although he describes himself as pro-vaccine.
By Jonathan Gardner , Ned Pagliarulo • Nov. 25, 2024 -
Win McNamee via Getty Images
Trump nominees want to slash and burn agencies. Will RFK Jr. and Oz do the same in healthcare?
Both Trump appointees have promised to bring sweeping changes to several healthcare agencies.
By Amy Baxter • Nov. 25, 2024 -
Permission granted by AbbVie
What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
AbbVie’s head of R&D cures has lofty ambitions to end diseases like HIV through a community of researchers that work as one.
By Michael Gibney • Nov. 19, 2024 -
Permission granted by Ron Tilles, Kevin Mercuri
ProfileLeft to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past
While Martin Shkreli smirked his way through a public securities fraud investigation, Ron Tilles became interim CEO of Turing Pharmaceuticals, ready or not. Here’s his story.
By Michael Gibney • Nov. 14, 2024 -
Chip Somodevilla via Getty Images
With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC
Speculation around pharma dealmaking and the next FDA commissioner has begun.
By Ned Pagliarulo , Ben Fidler • Nov. 8, 2024 -
Permission granted by Rallybio
Two former Alexion leaders fight through a tough market to maintain a rare disease biotech
Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey difficult.
By Michael Gibney • Nov. 5, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Cancer Care Visionaries
Leaders who envision a world without cancer through oncology innovation.
By Michael Gibney • Nov. 1, 2024 -
Getty Images via Getty Images
Big Pharma earnings hang hope on the next generation of blockbusters
Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.
By Michael Gibney • Oct. 31, 2024 -
Photo illustration: Industry Dive; Getty Images via Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Cell and Gene Therapy Pioneers
Leaders molding the cutting-edge cell and gene therapy field into tomorrow's cures.
By Michael Gibney • Oct. 30, 2024 -
eranicle via Getty Images
Q&AHow AZ’s respiratory wins are ramping up for a bigger prize in COPD
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
By Michael Gibney • Oct. 29, 2024 -
Permission granted by Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Biotech Pathfinders
Leaders solving biology's toughest puzzles and driving innovation forward.
By Michael Gibney • Oct. 23, 2024 -
George Clerk via Getty Images
With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble
Pfizer’s proxy battle with Starboard has gotten messy. It’s the latest in a series of activist investor campaigns that have been on the rise in recent years.
By Michael Gibney • Oct. 22, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Patient Champions
Leaders advancing health advocacy, DEI initiatives and better medicine access for patients.
By Meagan Parrish • Oct. 22, 2024 -
PharmaVoice/PharmaVoice
PharmaVoice 1002024 PharmaVoice 100s: Cardiometabolic All-Stars
Leaders tackling long-standing health needs with new solutions.
By Amy Baxter • Oct. 18, 2024 -
Permission granted by Parexel
Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with
From tech-related challenges to an ongoing staffing crunch, Parexel’s CEO explains what the clinical trials industry is up against.
By Meagan Parrish • Oct. 18, 2024 -
Christopher Furlong via Getty Images
Want to launch a blockbuster? An AstraZeneca exec breaks it down.
Even drugs with “blockbuster potential” often fall short of expectations. Here’s what can help a new medication pass the $1 billion mark.
By Alexandra Pecci • Oct. 16, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Trailblazers
Industry leaders charting new paths in science and business.
By Meagan Parrish • Oct. 16, 2024 -
Motortion via Getty Images
Regeneron takes the long-haul approach to oncology, stumbles and all
Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.
By Michael Gibney • Oct. 10, 2024 -
Permission granted by Biocom
Q&ACalifornia is a life sciences leader. Joe Panetta has been one of its most vocal advocates.
The president and CEO of Biocom California discusses the state’s strengths and weaknesses, current and emerging hubs, and the industry’s future.
By Alexandra Pecci • Oct. 1, 2024 -
Stock via Getty Images
Behind the rise of BMS’ Cobenfy, the first new schizophrenia drug in decades
The FDA OK for KarXT, now known as Cobenfy, demonstrates Bristol Myers Squibb’s dealmaking prowess and marks a turning point for a new generation of treatments.
By Kelly Bilodeau • Sept. 26, 2024 -
Permission granted by Roivant Sciences
Q&ARoivant’s magic trick: Finding the ‘weird-shaped’ pieces around Big Pharma’s cookie cutters
Roivant CEO Matt Gline leads the company on a unique path by placing bets on misfit drugs and technologies — and it’s working.
By Michael Gibney • Sept. 26, 2024 -
Permission granted by CRI
Q&A // First 90 DaysWant better cancer treatments? Make biopharma more like Silicon Valley
Alicia Zhou brings startup bona fides to the nonprofit Cancer Research Institute to promote defragmentation of the cancer research effort.
By Michael Gibney • Sept. 24, 2024
